Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report.

Medicine - 1 Jun 2018

Rosati Gerardo, Del Gaudio Nunzio, Scarano Enrico, Cifarelli Rosa Anna, Altucci Lucia, Bilancia Domenico

Abstract excerpt

RATIONALE: Regorafenib is an oral multikinase inhibitor and is approved as salvage therapy in the standard treatment of advanced colorectal cancer (CRC). Due to its limited efficacy, toxicity profile, and cost, it is necessary to identify those patients who may have the most benefit from regorafenib. In a previous case report, kinase insert domain receptor (KDR) mutation has been associated with exceptional...

Topics

Join the communities discussing this publication.

Carcinoembryonic Antigen
Disease-Free Survival
Fatal Outcome
Neoplasm Metastasis
Neoplasm Recurrence, Local

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Phenylurea Compounds

Vascular Endothelial Growth Factor Receptor-2

Source

Open in PubMed Open full text

Identifiers

PMID: 29924031
DOI: 10.1097/MD.0000000000011178
PMCID: PMC6023677

Genes

KDR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report.PMID 29924031Read ↗

[Regorafenib in patients with metastatic colorectal cancer: a review and an update].Semantic proximity Read ↗

Regorafenib Therapy as a Third-Line Treatment for Metastatic Colorectal Cancer: A Single Center Long Term ExperienceSemantic proximity Read ↗

Clinical and molecular assessment of regorafenib monotherapy.Semantic proximity Read ↗

Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).Semantic proximity Read ↗

Extraordinary Benefit of Regorafenib in Metastatic Cholangiocarcinoma: A Case Report.Semantic proximity Read ↗

Durable Disease Control with Regorafenib in a Patient with Metastatic KIT-Mutated Colorectal Cancer.Semantic proximity Read ↗

Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumabSemantic proximity Read ↗

Case analysis of a patient with NTRK gene fusion-positive colorectal cancer presenting with short-lived responseSemantic proximity Read ↗

Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.Semantic proximity Read ↗

Cases in the management of metastatic colorectal cancer: regorafenib as second-line therapy after FOLFOXIRI plus bevacizumab in a patient with a KRAS mutation.Semantic proximity Read ↗

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.Semantic proximity Read ↗

Successful Management of BRAF V600E-Mutated Metastatic Colorectal Cancer With Liver Dysfunction Using Encorafenib-Based Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.